Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderlyBeugeling, M., De Zee, J., Woerdenbag, H. J., Frijlink, H. W., Wilschut, J. C. & Hinrichs, W. L. J., 2019, In : Expert review of vaccines. 18, 9, p. 935-950 16 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Introduction: Respiratory syncytial virus (RSV) causes high morbidity and mortality rates among infants, young children, and the elderly worldwide. Unfortunately, a safe and effective vaccine is still unavailable. In 1966, a formalin-inactivated RSV vaccine failed and resulted in the death of two young children. This failure shifted research toward the development of subunit-based vaccines for pregnant women (to passively vaccinate infants) and the elderly. Among these subunit-based vaccines, the viral envelope glycoproteins show great potential as antigens. Areas covered: In this review, progress in the development of safe and effective subunit RSV vaccines based on the viral envelope glycoproteins and intended for pregnant women and the elderly, are reviewed and discussed. Studies published in the period 2012-2018 were included. Expert opinion: Researchers are close to bringing safe and effective subunit-based RSV vaccines to the market using the viral envelope glycoproteins as antigens. However, it remains a major challenge to elicit protective immunity, with a formulation that has sufficient (storage) stability. These issues may be overcome by using the RSV fusion protein in its pre-fusion conformation, and by formulating this protein as a dry powder. It may further be convenient to administer this powder via the pulmonary route.
|Number of pages||16|
|Journal||Expert review of vaccines|
|Early online date||25-Aug-2019|
|Publication status||Published - 2019|
- Attachment protein, fusion protein, nanoparticles, post-fusion, pre-fusion, respiratory syncytial virus, subunit-based vaccine, viral envelope glycoproteins, virosomes, virus-like particles, F NANOPARTICLE VACCINE, MONOPHOSPHORYL-LIPID-A, NF-KAPPA-B, RSV F, INTRANASAL IMMUNIZATION, IMMUNE-RESPONSE, INFLUENZA IMMUNIZATION, MATERNAL IMMUNIZATION, PROVIDES PROTECTION, YOUNG-CHILDREN